Provided by Tiger Fintech (Singapore) Pte. Ltd.

AzurRx Biopharma Inc.

3.45
+0.0000
Volume:- -
Turnover:2.20M
Market Cap:34.33M
PE:-0.22
High:3.45
Open:3.45
Low:3.45
Close:3.45
Loading ...

BRIEF-Azurrx Biopharma Inc Files Prospectus Relates To Resale Of Up To 26.1 Million Co's Shares By Selling Stockholders - SEC Filing

Reuters
·
02 Feb 2021

AzurRx BioPharma Announces Completion of Enrollment in First Cohort of Phase 2b OPTION 2 Extension Study of MS1819

GlobeNewswire
·
28 Jan 2021

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Addition of Two Clinical Trial Sites for MS1819 Phase 2b OPTION 2 Extension Study

StreetInsider
·
27 Jan 2021

AzurRx BioPharma Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients

GlobeNewswire
·
26 Jan 2021

AzurRx (AZRX) Starts Dosing in Pancreatic Insufficiency Study

Zacks
·
22 Jan 2021

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Beginning of MS1819 Extension Study with Initial Dosing of Two Patients

StreetInsider
·
22 Jan 2021

2 “Strong Buy” Penny Stocks That Could See Outsized Gains

TipRanks
·
21 Jan 2021

AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients

GlobeNewswire
·
21 Jan 2021

BRIEF-Azurrx Biopharma Files For Offering Of 16.0 Mln Shares Of Common Stock By The Selling Stockholder - SEC Filing

Reuters
·
14 Jan 2021

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX), First Wave, Receive Notice of Allowance for Niclosamide Patent

StreetInsider
·
13 Jan 2021

AzurRx BioPharma and First Wave Bio Announce Allowance of U.S. Patent Application for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections

GlobeNewswire
·
12 Jan 2021

BRIEF-Azurrx Biopharma CEO Issues Letter To Shareholders

Reuters
·
09 Jan 2021

AzurRx BioPharma CEO Issues Letter to Shareholders

GlobeNewswire
·
08 Jan 2021

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Participation in Biotech Showcase Digital 2021 Conference

StreetInsider
·
07 Jan 2021

AzurRx BioPharma to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference

GlobeNewswire
·
06 Jan 2021

AzurRx BioPharma to Participate in 10th Annual LifeSci Partners Corporate Access Event

GlobeNewswire
·
05 Jan 2021

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Worldwide License Agreement with First Wave Bio, $8M Offerings

StreetInsider
·
05 Jan 2021

BRIEF-Azurrx Biopharma Inc Signed An Exclusive Worldwide Licensing Agreement With First Wave Bio, Inc.

Reuters
·
04 Jan 2021

AzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary Niclosamide Formulations to Treat Immune Checkpoint Inhibitor-Associated Colitis and COVID-19 Gastrointestinal Infections

GlobeNewswire
·
04 Jan 2021

AzurRx BioPharma Announces $8.0 Million Offerings

GlobeNewswire
·
04 Jan 2021